Literature DB >> 25327441

Involvement of retrotransposon L1 in stemness and cellular plasticity.

Panagiotis Apostolou1, Maria Toloudi1, Marina Chatziioannou1, Eleni Kourtidou1, Georgia Mimikakou1, Ioanna Vlachou1, Aikaterini Chlichlia2, Ioannis Papasotiriou1.   

Abstract

Epithelial-to-mesenchymal transition (EMT) as well as the reverse process, mesenchymal-to-epithelial transition (MET) is important during embryogenesis. EMT is also involved in cancer invasion and metastasis, and can generate cells with properties similar to those of stem cells. Retrotransposons can rearrange the genome by inserting DNA in new loci, thus inducing mutations. This study examines the gene expression of transcription factors involved in EMT and MET. In the second experimental panel, the gene expression of L1 retrotransposon was studied. L1-open reading frame (ORF) 2 mRNA was found to be expressed both in cancer and cancer stem cells, while L1-ORF1 mRNA was expressed only in cancer cells. The suppression of L1-ORF2 gene expression demonstrated that this retrotransposon might affect EMT in colon cancer stem cells. This study highlights that the EMT process seems to differ between cancer cells and cancer stem cells, and that transposable elements seem to be involved in the process, influencing cellular plasticity.

Entities:  

Keywords:  LINE-1; cancer; cancer stem cells; cell plasticity; retrotransposon

Mesh:

Substances:

Year:  2014        PMID: 25327441     DOI: 10.3109/15419061.2014.970270

Source DB:  PubMed          Journal:  Cell Commun Adhes        ISSN: 1543-5180


  2 in total

1.  L1 retrotransposon expression in circulating tumor cells.

Authors:  Ioannis Papasotiriou; Katerina Pantopikou; Panagiotis Apostolou
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

2.  Biomarker potential of repetitive-element transcriptome in lung cancer.

Authors:  Macarena Arroyo; Rocío Bautista; Rafael Larrosa; Manuel Ángel Cobo; M Gonzalo Claros
Journal:  PeerJ       Date:  2019-12-19       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.